Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Severe case 10% Improvement Relative Risk Metformin for COVID-19  Bidari et al.  Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 406 patients in Iran (February - April 2020) Lower severe cases with metformin (not stat. sig., p=0.53) c19early.org Bidari et al., Cureus, October 2023 Favors metformin Favors control

Development of a Scoring Method Based on a Chest CT Scan to Determine the Outcomes of COVID-19 Patients

Bidari et al., Cureus, doi:10.7759/cureus.47354
Oct 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 84 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 406 COVID-19 patients in Iran, showing lower risk of severe cases with metformin use in unadjusted results, without statistical significance.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of severe case, 10.5% lower, RR 0.90, p = 0.53, treatment 29 of 80 (36.2%), control 132 of 326 (40.5%), NNT 24.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bidari et al., 19 Oct 2023, retrospective, Iran, peer-reviewed, 8 authors, study period February 2020 - April 2020. Contact: mahyanaderkhani2023@gmail.com.
This PaperMetforminAll
Development of a Scoring Method Based on a Chest CT Scan to Determine the Outcomes of COVID-19 Patients
Milad Ali Bidari, Milad Elham Zarei, Milad Morteza Hassanzadeh, Milad Gholizadeh Mesgarha, Arash Pour Mohammad, Reyhaneh Shafiei, Mahsa Mortaja, Mahya Naderkhani
Cureus, doi:10.7759/cureus.47354
Introduction As COVID-19 shifts from pandemic urgency to endemic management, healthcare systems are faced with the evolving challenge of providing optimized care and adept resource allocation in this evolving landscape of the disease. However, the timely management and accurate assessment of disease severity remains a cornerstone of effective treatment. This study presents a pioneering scoring system, based on the primary chest CT scan findings, to predict patient outcomes and to equip clinicians with a tool that can expedite decision-making. Method A retrospective cohort study was conducted involving 406 confirmed COVID-19 cases referred to two of our hospitals in Tehran, between February and April 2020. Radiographic and CT scan data were sourced from the imaging archive system and evaluated by a certified radiologist. We devised distinct severity scores for CT findings, demographic factors, and clinical indicators. These were synthesized into a comprehensive severity score to forecast critical patient outcomes, such as mortality, ICU admission, intubation, or extended hospitalization. Of the total cases, 161 (39.7%) were classified as severe, while 245 (60%) fell into the low or moderate severity category. Results The mean score of demographic, CT scan, and clinical characteristics was significantly higher for those in the severe COVID-19 than the non-severe group. The cutoff score for predicting the outcomes in COVID-19 patients for demographic, clinical, and chest CT scan factors was 2.5, 9.5, and 8.5, respectively. Multivariate analysis indicated that each unit increase in these scores elevated the odds of fatal outcomes by 24%, 2.8%, and 12%, respectively. Then, using the comprehensive severity score, which is the sum of the above scores, we further predicted the disease severity. Conclusion The findings suggest that our innovative scoring system, based on initial chest CT scan findings, serves as a robust predictor of COVID-19 outcomes.
Additional Information Author Contributions All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.
References
Abdel-Tawab, Basha, Ibrahim, A simple chest CT score for assessing the severity of pulmonary involvement in COVID-19, Egypt J Radiol Nucl Med, doi:10.1186/s43055-021-00525-x
Aziz-Ahari, Keyhanian, Mamishi, Mahmoudi, Bastani et al., Chest CT severity score: assessment of COVID-19 severity and short-term prognosis in hospitalized Iranian patients, Wien Med Wochenschr, doi:10.1007/s10354-022-00914-5
Bahadorizadeh, Emamikhah, Mohammad, Mesgarha, Simultaneous occurrence of cerebral venous sinus thrombosis and immune thrombocytopenic purpura in a patient with a history of COVID-19 infection, Neurol Ther, doi:10.1007/s40120-021-00294-9
Bidari, Asgarian, Mohammad, Naderi, Anaraki et al., Immune thrombocytopenic purpura secondary to COVID-19 vaccination: a systematic review, Eur J Haematol, doi:10.1111/ejh.13917
Bidari, Hassanzadeh, Naderkhani, Predictors of critical COVID-19 in an Iranian population: age and disabilities play a special role, Med J Islam Repub Iran, doi:10.47176/mjiri.35.94
Bidari, None, Cureus, doi:10.7759/cureus.4735410of10
Hajsadeghi, Mesgarha, Shahrbabaki, Pishgahi, Fard Azar et al., Constrictive pericarditis following inactivated virus COVID-19 vaccine: a case report with review of the literature, Radiol Case Rep, doi:10.1016/j.radcr.2022.07.021
He, Deng, Li, Coronavirus disease 2019: what we know?, J Med Virol, doi:10.1002/jmv.25766
Li, Wu, Wu, Guo, Chen et al., The clinical and chest CT features associated with severe and critical COVID-19 pneumonia, Invest Radiol, doi:10.1097/RLI.0000000000000672
Mashayekhi, Seirafianpour, Mohammad, Goodarzi, Severe and life-threatening COVID-19-related mucocutaneous eruptions: a systematic review, Int J Clin Pract, doi:10.1111/ijcp.14720
Mohammad, Mashayekhi, Seirafianpour, Mesgarha, Goodarzi, COVID-19 and COVID-19 vaccine-related dermatological reactions: an interesting case series with a narrative review of the potential critical and non-critical mucocutaneous adverse effects related to virus, therapy, and the vaccination, Clin Case Rep, doi:10.1002/ccr3.5775
Moradians, Amiri, Bahadorizadeh, Mesgarha, Sadeghi, Concurrent COVID-19 and pneumocystis carinii pneumonia in a patient subsequently found to have underlying hairy cell leukemia, Radiol Case Rep, doi:10.1016/j.radcr.2022.06.026
Seirafianpour, Pourriyahi, Mesgarha, Mohammad, Shaka et al., A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders, Dermatol Ther, doi:10.1111/dth.15461
Singhal, A review of coronavirus disease-2019 (COVID-19), Indian J Pediatr, doi:10.1007/s12098-020-03263-6
Wang, Wu, Liu, Predicting progression to severe COVID-19 using the PAINT score, BMC Infect Dis, doi:10.1186/s12879-022-07466-4
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit